^
Association details:
| Biomarker: | HRAS G13R |
|---|---|
| Cancer: | Thyroid Gland Carcinoma |
| Drug: | Koselugo (selumetinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
NF2 loss promotes oncogenic RAS-induced thyroid cancers via YAP-dependent transactivation of RAS proteins and sensitizes them to MEK inhibition
Excerpt:
There was a trend for greater sensitivity to AZD6244 in RAS mutant thyroid cancer cell lines that were merlin null or low as compared to merlin wild-type cell linesreater sensitivity to AZD6244 in RAS mutant thyroid cancer cell lines that were merlin null or low as compared to merlin wild-type cell lines...
DOI:
10.1158/2159-8290.CD-15-0330
